Cargando…

Shared-care models are highly effective and cost-effective for managing chronic hepatitis B in China: reinterpreting the primary care and specialty divide

BACKGROUND: We evaluate the impact and cost-effectiveness of shared primary-specialty chronic hepatitis B (CHB) care models in China. METHODS: We constructed a decision-tree Markov model to simulate hepatitis B virus (HBV) disease progression in a cohort of 100,000 CHB individuals aged ≥18 years ove...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Lei, Liu, Hanting, Zou, Zhuoru, Su, Shu, Ong, Jason J., Ji, Fanpu, Cui, Fuqiang, Chan, Po-lin, Ning, Qin, Li, Rui, Shen, Mingwang, Fairley, Christopher K., Liu, Lan, Seto, Wai-Kay, Wong, William C.W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10326699/
https://www.ncbi.nlm.nih.gov/pubmed/37424676
http://dx.doi.org/10.1016/j.lanwpc.2023.100737
_version_ 1785069476971020288
author Zhang, Lei
Liu, Hanting
Zou, Zhuoru
Su, Shu
Ong, Jason J.
Ji, Fanpu
Cui, Fuqiang
Chan, Po-lin
Ning, Qin
Li, Rui
Shen, Mingwang
Fairley, Christopher K.
Liu, Lan
Seto, Wai-Kay
Wong, William C.W.
author_facet Zhang, Lei
Liu, Hanting
Zou, Zhuoru
Su, Shu
Ong, Jason J.
Ji, Fanpu
Cui, Fuqiang
Chan, Po-lin
Ning, Qin
Li, Rui
Shen, Mingwang
Fairley, Christopher K.
Liu, Lan
Seto, Wai-Kay
Wong, William C.W.
author_sort Zhang, Lei
collection PubMed
description BACKGROUND: We evaluate the impact and cost-effectiveness of shared primary-specialty chronic hepatitis B (CHB) care models in China. METHODS: We constructed a decision-tree Markov model to simulate hepatitis B virus (HBV) disease progression in a cohort of 100,000 CHB individuals aged ≥18 years over their lifetime (aged 80). We evaluated the population impacts and cost-effectiveness in three scenarios: (1) status quo; (2) shared-care model with HBV testing and routine CHB follow-ups in primary care and antiviral treatment initiation in specialty care; and (3) shared-care model with HBV testing, treatment initiation and routine CHB follow-up in primary care and treatment for predetermined conditions in specialty care. We evaluated from a healthcare provider's perspective with 3% discounting rate and a willingness-to-pay (WTP) threshold of 1-time China's GDP. FINDINGS: Compared with status quo, scenario 2 would result in an incremental cost of US$5.79–132.43m but a net gain of 328–16,993 quality-adjusted life years (QALYs) and prevention of 39–1935 HBV-related deaths over cohort's lifetime. Scenario 2 was not cost-effective with a WTP of 1-time GDP per capita, but became cost-effective when treatment initiation rate increased to 70%. In contrast, compared with status quo, secnario 3 would save US$144.59–192.93m in investment and achieve a net gain of 23,814–30,476 QALYs and prevention of 3074–3802 HBV-related deaths. Improving HBV antiviral treatment initiation among eligible CHB individuals substantially improved the cost-effectiveness of the shared-care models. INTERPRETATION: Shared-care models with HBV testing, follow up and referring of predetermined conditions to specialty care at an appropriate time, especially antiviral treatment initiation in primary care, are highly effective and cost-effective in China. FUNDING: 10.13039/501100001809National Natural Science Foundation of China.
format Online
Article
Text
id pubmed-10326699
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-103266992023-07-08 Shared-care models are highly effective and cost-effective for managing chronic hepatitis B in China: reinterpreting the primary care and specialty divide Zhang, Lei Liu, Hanting Zou, Zhuoru Su, Shu Ong, Jason J. Ji, Fanpu Cui, Fuqiang Chan, Po-lin Ning, Qin Li, Rui Shen, Mingwang Fairley, Christopher K. Liu, Lan Seto, Wai-Kay Wong, William C.W. Lancet Reg Health West Pac Articles BACKGROUND: We evaluate the impact and cost-effectiveness of shared primary-specialty chronic hepatitis B (CHB) care models in China. METHODS: We constructed a decision-tree Markov model to simulate hepatitis B virus (HBV) disease progression in a cohort of 100,000 CHB individuals aged ≥18 years over their lifetime (aged 80). We evaluated the population impacts and cost-effectiveness in three scenarios: (1) status quo; (2) shared-care model with HBV testing and routine CHB follow-ups in primary care and antiviral treatment initiation in specialty care; and (3) shared-care model with HBV testing, treatment initiation and routine CHB follow-up in primary care and treatment for predetermined conditions in specialty care. We evaluated from a healthcare provider's perspective with 3% discounting rate and a willingness-to-pay (WTP) threshold of 1-time China's GDP. FINDINGS: Compared with status quo, scenario 2 would result in an incremental cost of US$5.79–132.43m but a net gain of 328–16,993 quality-adjusted life years (QALYs) and prevention of 39–1935 HBV-related deaths over cohort's lifetime. Scenario 2 was not cost-effective with a WTP of 1-time GDP per capita, but became cost-effective when treatment initiation rate increased to 70%. In contrast, compared with status quo, secnario 3 would save US$144.59–192.93m in investment and achieve a net gain of 23,814–30,476 QALYs and prevention of 3074–3802 HBV-related deaths. Improving HBV antiviral treatment initiation among eligible CHB individuals substantially improved the cost-effectiveness of the shared-care models. INTERPRETATION: Shared-care models with HBV testing, follow up and referring of predetermined conditions to specialty care at an appropriate time, especially antiviral treatment initiation in primary care, are highly effective and cost-effective in China. FUNDING: 10.13039/501100001809National Natural Science Foundation of China. Elsevier 2023-03-20 /pmc/articles/PMC10326699/ /pubmed/37424676 http://dx.doi.org/10.1016/j.lanwpc.2023.100737 Text en © 2023 Published by Elsevier Ltd. https://creativecommons.org/licenses/by-nc-nd/3.0/igo/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/igo/).
spellingShingle Articles
Zhang, Lei
Liu, Hanting
Zou, Zhuoru
Su, Shu
Ong, Jason J.
Ji, Fanpu
Cui, Fuqiang
Chan, Po-lin
Ning, Qin
Li, Rui
Shen, Mingwang
Fairley, Christopher K.
Liu, Lan
Seto, Wai-Kay
Wong, William C.W.
Shared-care models are highly effective and cost-effective for managing chronic hepatitis B in China: reinterpreting the primary care and specialty divide
title Shared-care models are highly effective and cost-effective for managing chronic hepatitis B in China: reinterpreting the primary care and specialty divide
title_full Shared-care models are highly effective and cost-effective for managing chronic hepatitis B in China: reinterpreting the primary care and specialty divide
title_fullStr Shared-care models are highly effective and cost-effective for managing chronic hepatitis B in China: reinterpreting the primary care and specialty divide
title_full_unstemmed Shared-care models are highly effective and cost-effective for managing chronic hepatitis B in China: reinterpreting the primary care and specialty divide
title_short Shared-care models are highly effective and cost-effective for managing chronic hepatitis B in China: reinterpreting the primary care and specialty divide
title_sort shared-care models are highly effective and cost-effective for managing chronic hepatitis b in china: reinterpreting the primary care and specialty divide
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10326699/
https://www.ncbi.nlm.nih.gov/pubmed/37424676
http://dx.doi.org/10.1016/j.lanwpc.2023.100737
work_keys_str_mv AT zhanglei sharedcaremodelsarehighlyeffectiveandcosteffectiveformanagingchronichepatitisbinchinareinterpretingtheprimarycareandspecialtydivide
AT liuhanting sharedcaremodelsarehighlyeffectiveandcosteffectiveformanagingchronichepatitisbinchinareinterpretingtheprimarycareandspecialtydivide
AT zouzhuoru sharedcaremodelsarehighlyeffectiveandcosteffectiveformanagingchronichepatitisbinchinareinterpretingtheprimarycareandspecialtydivide
AT sushu sharedcaremodelsarehighlyeffectiveandcosteffectiveformanagingchronichepatitisbinchinareinterpretingtheprimarycareandspecialtydivide
AT ongjasonj sharedcaremodelsarehighlyeffectiveandcosteffectiveformanagingchronichepatitisbinchinareinterpretingtheprimarycareandspecialtydivide
AT jifanpu sharedcaremodelsarehighlyeffectiveandcosteffectiveformanagingchronichepatitisbinchinareinterpretingtheprimarycareandspecialtydivide
AT cuifuqiang sharedcaremodelsarehighlyeffectiveandcosteffectiveformanagingchronichepatitisbinchinareinterpretingtheprimarycareandspecialtydivide
AT chanpolin sharedcaremodelsarehighlyeffectiveandcosteffectiveformanagingchronichepatitisbinchinareinterpretingtheprimarycareandspecialtydivide
AT ningqin sharedcaremodelsarehighlyeffectiveandcosteffectiveformanagingchronichepatitisbinchinareinterpretingtheprimarycareandspecialtydivide
AT lirui sharedcaremodelsarehighlyeffectiveandcosteffectiveformanagingchronichepatitisbinchinareinterpretingtheprimarycareandspecialtydivide
AT shenmingwang sharedcaremodelsarehighlyeffectiveandcosteffectiveformanagingchronichepatitisbinchinareinterpretingtheprimarycareandspecialtydivide
AT fairleychristopherk sharedcaremodelsarehighlyeffectiveandcosteffectiveformanagingchronichepatitisbinchinareinterpretingtheprimarycareandspecialtydivide
AT liulan sharedcaremodelsarehighlyeffectiveandcosteffectiveformanagingchronichepatitisbinchinareinterpretingtheprimarycareandspecialtydivide
AT setowaikay sharedcaremodelsarehighlyeffectiveandcosteffectiveformanagingchronichepatitisbinchinareinterpretingtheprimarycareandspecialtydivide
AT wongwilliamcw sharedcaremodelsarehighlyeffectiveandcosteffectiveformanagingchronichepatitisbinchinareinterpretingtheprimarycareandspecialtydivide